AtriCure (NASDAQ:ATRC) Insider Sells $108,900.00 in Stock

Key Points

• Insider Justin Noznesky sold 3,000 shares of AtriCure at an average price of $36.30, reducing his stake by 3.45% and retaining 83,964 shares valued at over $3 million.
• AtriCure's stock has a market capitalization of $1.75 billion and recently reported a 17.1% increase in quarterly revenue year-over-year, amounting to $136.14 million.
• Analysts have expressed a positive outlook, with a consensus target price of $50.89 and multiple firms upgrading AtriCure's rating to "buy."

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) insider Justin J. Noznesky sold 3,000 shares of the company's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $36.30, for a total value of $108,900.00. Following the transaction, the insider directly owned 83,964 shares in the company, valued at $3,047,893.20. The trade was a 3.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

AtriCure Stock Down 0.6%

Shares of NASDAQ ATRC traded down $0.23 during mid-day trading on Friday, reaching $36.43. 676,041 shares of the company traded hands, compared to its average volume of 415,295. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. The stock has a market cap of $1.81 billion, a PE ratio of -47.31 and a beta of 1.62. The company's fifty day moving average is $34.76 and its two-hundred day moving average is $33.42. AtriCure, Inc. has a fifty-two week low of $25.57 and a fifty-two week high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The medical device company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.15) by $0.13. AtriCure had a negative return on equity of 4.20% and a negative net margin of 7.27%.The business had revenue of $136.14 million for the quarter, compared to analyst estimates of $130.17 million. During the same quarter in the prior year, the firm posted ($0.17) EPS. The firm's revenue for the quarter was up 17.1% on a year-over-year basis. AtriCure has set its FY 2025 guidance at -0.390--0.340 EPS. On average, analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current year.

Institutional Investors Weigh In On AtriCure

A number of hedge funds and other institutional investors have recently bought and sold shares of ATRC. Geneos Wealth Management Inc. acquired a new stake in shares of AtriCure in the 2nd quarter valued at $37,000. First Horizon Advisors Inc. increased its stake in shares of AtriCure by 135.3% in the 1st quarter. First Horizon Advisors Inc. now owns 1,447 shares of the medical device company's stock valued at $47,000 after buying an additional 832 shares during the period. US Bancorp DE increased its stake in shares of AtriCure by 98.1% in the 1st quarter. US Bancorp DE now owns 1,593 shares of the medical device company's stock valued at $51,000 after buying an additional 789 shares during the period. Heck Capital Advisors LLC bought a new position in shares of AtriCure in the 4th quarter worth $60,000. Finally, State of Wyoming boosted its position in shares of AtriCure by 21.9% in the 4th quarter. State of Wyoming now owns 2,481 shares of the medical device company's stock worth $76,000 after purchasing an additional 446 shares during the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ATRC has been the subject of a number of recent research reports. Wall Street Zen raised AtriCure from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Needham & Company LLC increased their target price on AtriCure from $44.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday, July 30th. Finally, BTIG Research set a $54.00 target price on AtriCure in a report on Wednesday, July 30th. Nine equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average price target of $50.89.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.